FeesSafety
Pluang+

Vertex Pharmaceuticals remains a Buy with strong cash flow and promising drug pipeline.

Analyst Insights
20 Nov 2026, 14:21 WIB
Seeking Alpha
View Source
Bullish
Vertex Pharmaceuticals remains a Buy with strong cash flow and promising drug pipeline.

Vertex Pharmaceuticals is rated as a Buy due to its durable cash flow from its cystic fibrosis (CF) franchise, which accounts for about 60% of its market value and is expected to grow steadily with patent protection. The company also has promising non-CF drug opportunities like Journavx and Povetacicept, with an FDA decision expected by November 30 that could expand its market potential. These factors support Vertex's long-term market outperformance despite some pricing and trial risks.

Vertex Pharmaceuticals shares trade at USD 526.00 on Pluang as of Nov 20, 2026 19:11 WIB, close to its 52-week high of USD 559.41 and well above the 52-week low of USD 422.32. Despite a 1.03% gain in the last day, the platform shows a strong sell sentiment with 98% of orders being sell and only 2% buy. This contrasts with the company's positive outlook on new drug approvals, highlighting a cautious market stance at this time.

More News (VRTX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App